ArticleFrontiers in immunology2025
Development and validation of a nomogram for predicting overall survival in patients with primary central nervous system germ cell tumors.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for adverse events following rabies vaccination: a multivariate analysis of real-world data.Frontiers in public health · 2026Article
- Machine learning prediction of overall survival in patients with cT1b renal cell carcinoma after surgical resection using the SEER database.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary central nervous system (CNS) germ cell tumors (GCTs) are common neoplasms in the CNS of pediatric and adolescent patients. This study aimed to identify prognostic factors associated with CNS GCTs and establish an effective nomogram for predicting overall survival (OS) in patients with CNS GCTs. Methods: The development cohort including 1166 CNS GCTs patients was selected from Surveillance, Epidemiology, and End Results (SEER) program between 2000 and 2021. An additional 165 CNS GCTs patients treated at the Sun Yat-sen University Cancer Center (SYSUCC) between 1997 and 2019 were included as validation cohort. Results: The nomogram incorporated the variables screened by multivariate Cox regression analysis, which included age, sex, histopathology, dissemination, tumor size, radiotherapy, and chemotherapy. The model demonstrated good discriminative performance, with C-index of 0.773 (95% CI, 0.734 - 0.812) and 0.712 (95% CI, 0.599- 0.825) in the development and validation cohorts, respectively. Calibration curves and area under the time-dependent receiver operating characteristic curve (time-dependent AUC) verified the superiority of our nomogram for clinical usefulness. Decision curve analysis (DCA) further illustrated the potential clinical value of the nomogram for treatment decision-making. Additionally, we established a comprehensive risk grouping system that effectively categorized patients into distinct prognostic groups based on their predicted outcomes. Conclusion: A precise prognostic nomogram was developed for patients with CNS GCTs, utilizing seven independent prognostic factors. It demonstrated satisfactory performance and clinical usability, aiding clinicians in accurately estimating prognosis and guiding the treatment and long-term management of patients with CNS GCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.